Publications
| Title | Abstract | Year(sorted descending) Filter | PMID Filter |
|---|
| self-report and clinical response to peyronie's disease treatment: peyronie's disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies. | to evaluate the clinical usefulness of the peyronie's disease questionnaire (pdq). the relationship between subject-reported changes in pdq psychosexual symptoms and clinical response to peyronie's disease (pd) treatment was examined. | 2015 | 26199168 |
| the collagenase of the bacterium clostridium histolyticum for the treatment of capsular fibrosis after silicone implants. | the main part of the fibrotic capsule in capsular contracture is collagen. the collagenase of the bacterium clostridium histolyticum is u.s. food and drug administration approved for the treatment of dupuytren contracture and might be capable of dissolving the fibrotic capsule surrounding silicone implants. | 2015 | 26171751 |
| intralesional injection of interferon-α2b improves penile curvature in men with peyronie's disease independent of plaque location. | collagenase clostridium histolyticum is the only fda (food and drug administration) approved treatment for peyronie's disease. however, to our knowledge collagenase clostridium histolyticum has not been studied in men with ventral plaques. given this limitation and the paucity of literature on ventral plaque outcomes, we compared the results of peyronie's disease treatment in men with different plaque locations treated with intralesional interferon-α2b. | 2015 | 26144333 |
| collagenase clostridium histolyticum (xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis. | to evaluate the treatment effect of collagenase clostridium histolyticum (cch) in a rat model of urethral fibrosis. | 2015 | 26126692 |
| therapeutic advances in the treatment of peyronie's disease. | peyronie's disease (pd) is an under-diagnosed condition with prevalence in the male population as high as 9%. it is a localized connective tissue disorder of the penis characterized by scarring of the tunica albuginea. its pathophysiology, however, remains incompletely elucidated. for the management of the acute phase of pd, there are currently numerous available oral drugs, but the scientific evidence for their use is weak. in terms of intralesional injections, collagenase clostridium histolyti ... | 2015 | 26097120 |
| dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (cordless [collagenase option for reduction of dupuytren long-term evaluation of safety study]): 5-year data. | collagenase option for reduction of dupuytren long-term evaluation of safety study was a 5-year noninterventional follow-up study to determine long-term efficacy and safety of collagenase clostridium histolyticum (cch) treatment for dupuytren contracture. | 2015 | 26096221 |
| [effect of dopamine on the activity of matrix metalloproteinases and degradation of dentin collagen]. | to investigate the inhibition effect of dopamine on the activity of matrix metalloproteinases (mmp) and the effect of dopamine on degradation of dentin collagen for its potential use in caries treatment and dentin adhesive. | 2015 | 26081862 |
| re: clinical efficacy of collagenase clostridium histolyticum in the treatment of peyronie's disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase iii studies. | 2015 | 26460876 | |
| outcome of dupuytren's contractures after collagenase clostridium histolyticum injection: a single institution experience. | 2015 | 26397518 | |
| collagenase clostridium histolyticum for the pharmacological management of peyronie's disease. | peyronie's disease (pd) is defined as the abnormal accumulation of connective tissue in the tunica albuginea of the penis, and is an ongoing physical and psychological challenge for thousands of americans. in vitro studies in the 1950s uncovered the potential of collagenase clostridium histolyticum (cch) to disrupt the collagen-containing plaques in pd, and opened the door to more in-depth clinical trials. results indicated that with multiple dosage cycles followed by plaque modeling, penile cur ... | 2015 | 26380384 |
| delayed manipulation after collagenase clostridium histolyticum injection for dupuytren contracture. | collagenase clostridium histolyticum (cch) injection for dupuytren contracture was approved in the usa in 2010. current fda guidelines stipulate that finger manipulation occurs the day following injection. to investigate the safety and efficacy of delaying manipulation to 2 or 4 days following cch injection, we conducted a prospective, randomized trial at two sites. | 2015 | 26330801 |
| re: surgical correction of persistent peyronie's disease following collagenase clostridium histolyticum treatment. | 2015 | 26292883 | |
| salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. | collagenase clostridium histolyticum was approved for clinical use in 2010 and has become an accepted treatment modality for dupuytren's contracture. because longitudinal experience with injectable collagenase remains limited, the effect of treatment on future surgery is not well defined. | 2015 | 26017606 |
| engineering d-amino acid containing collagen like peptide at the cleavage site of clostridium histolyticum collagenase for its inhibition. | collagenase is an important enzyme which plays an important role in degradation of collagen in wound healing, cancer metastasis and even in embryonic development. however, the mechanism of this degradation has not yet been completely understood. in the field of biomedical and protein engineering, the design and development of new peptide based materials is of main concern. in the present work an attempt has been made to study the effect of dala in collagen like peptide (imino-poor region of type ... | 2015 | 25973613 |
| acceleration of callus formation during fracture healing using basic fibroblast growth factor-kidney disease domain-collagen-binding domain fusion protein combined with allogenic demineralized bone powder. | to repair fractures with large bone defects or gaps, demineralized allogenic bone matrix (dbm) is often applied to the fracture site. however, studies have shown that the use of dbm alone has limited efficacy for repairing fractures. in the present study, we developed an allogenic demineralized bone powder (dbp) with basic fibroblast-derived growth factor containing a polycystic kidney disease (pkd) domain and collagen-binding domain (cbd) from clostridium histolyticum collagenase (colh) and inv ... | 2015 | 25956801 |
| collagenase clostridium histolyticum for the treatment of peyronie's disease: the development of this novel pharmacologic approach. | the conception of collagenase clostridium histolyticum (cch) as treatment for peyronie's disease (pd) was a vital first step in providing a nonsurgical, minimally invasive fda-approved treatment for men with pd. | 2015 | 25940867 |
| evaluation of species differences and the effects of storage duration and temperature on the anticollagenase efficacy of canine, feline, and equine serum on in vitro corneal degradation. | objective to evaluate species differences and effects of storage duration and temperature on the anticollagenase efficacy of canine, feline, and equine serum on in vitro corneal degradation. samples corneas and serum from dogs, cats, and horses. procedures clinically normal corneas from dogs, cats, and horses were harvested within 2 hours after euthanasia. serum samples from dogs, cats, and horses were collected and pooled by species. corneal specimens were incubated with collagenase derived fro ... | 2015 | 26512545 |
| structures of three polycystic kidney disease-like domains from clostridium histolyticum collagenases colg and colh. | clostridium histolyticum collagenases colg and colh are segmental enzymes that are thought to be activated by ca(2+)-triggered domain reorientation to cause extensive tissue destruction. the collagenases consist of a collagenase module (s1), a variable number of polycystic kidney disease-like (pkd-like) domains (s2a and s2b in colh and s2 in colg) and a variable number of collagen-binding domains (s3 in colh and s3a and s3b in colg). the x-ray crystal structures of ca(2+)-bound holo s2b (1.4 å r ... | 2015 | 25760606 |
| clinical efficacy of collagenase clostridium histolyticum in the treatment of peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase iii studies. | to examine the efficacy of intralesional collagenase clostridium histolyticum (cch) in defined subgroups of patients with peyronie's disease (pd). | 2015 | 25711400 |
| collagenase treatment of dupuytren's contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome. | treatment of dupuytren's contracture (dc) with collagenase clostridium histolyticum (cch) consists of injection followed by finger manipulation. we used a modified method, injecting a higher dose than recommended on the label into several parts of the cord, which allows treatment of multiple joint contractures in 1 session and may increase efficacy. we studied the occurrence of skin tears and short-term outcome with this procedure. | 2015 | 25695745 |
| responsiveness of the peyronie's disease questionnaire (pdq). | in order to reliably assess treatment effectiveness, patient-reported outcome instruments must demonstrate adequate psychometric properties. | 2015 | 25664497 |
| early outcomes of a sequential series of 144 patients with dupuytren's contracture treated by collagenase injection using an increased dose, multi-cord technique. | collagenase clostridium histolyticum is the first and only united states food and drug association approved nonsurgical treatment for patients with a palpable dupuytren's contracture cord. however, the food and drug association has only approved injection of 0.58 mg of this enzyme into one palpable dupuytren's contracture cord at a time. this review reports on the early outcome of 144 patients treated with the entire bottle of enzyme, approximately 0.78 mg, along with use of a novel slow intraco ... | 2015 | 24698852 |
| safety and tolerability of collagenase clostridium histolyticum and fasciectomy for dupuytren's contracture. | safety was evaluated for collagenase clostridium histolyticum (cch) based on 11 clinical trials (n = 1082) and compared with fasciectomy data in a structured literature review of 48 european studies (n = 7727) for treatment of dupuytren's contracture. incidence of adverse events was numerically lower with cch vs. equivalent complications from fasciectomy (median [range] incidence), including nerve injury (0% vs. 3.8% [0%-50+%]), neurapraxia (4.4% vs. 9.4% [0%-51.3%]), complex regional pain syndr ... | 2015 | 24698851 |
| collagenase clostridium histolyticum in patients with dupuytren's contracture: results from point x, an open-label study of clinical and patient-reported outcomes. | in point x, a study designed to reflect clinical practice and patient treatment choices, 254 european patients received open-label collagenase for dupuytren's contracture. the most severely affected joint was treated first in 74% of patients. in total, 52%, 41%, 7%, and 1% of patients selected the little, ring, middle, and index finger, respectively; 79% had one or two joints treated. only 9% of patients (n = 24) received 4 or 5 injections. the mean improvement in total passive extension deficit ... | 2015 | 24470559 |
| clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with peyronie's disease: a phase 3 open-label study. | collagenase clostridium histolyticum (cch; xiaflex, auxilium pharmaceuticals, inc., chesterbrook, pa, usa) is a food and drug administration-approved, intralesional treatment for peyronie's disease (pd). | 2015 | 25388099 |
| surgical correction of persistent peyronie's disease following collagenase clostridium histolyticum treatment. | collagenase clostridium histolyticum (cch) is an food and drug administration-approved intralesional injection for treatment of peyronie's disease (pd) that has been shown to reduce penile curvature deformity and pd symptom bother in phase 2b and phase 3 placebo-controlled clinical trials. for some patients, nonsurgical treatment with cch may not sufficiently improve penile curvature, and surgical correction may be pursued following cch therapy. | 2015 | 25345351 |
| injectable clostridium histolyticum collagenase as a potential treatment for uterine fibroids. | purified clostridium histolyticum collagenase (chc), an food and drug administration-approved drug that does not affect nerves or blood vessels, was assessed as a potential treatment for fibroids in this proof-of-principle study. fibroids (1-4 cm, capsules intact) and myometrial specimens from 5 patients were injected posthysterectomy with chc or vehicle containing methylene blue and incubated for 24 hours. percentage of collagen-stained area was estimated using masson-trichrome-stained slides. ... | 2014 | 25332216 |
| 2013-2014 updates in peyronie's disease management. | the number of patients presenting with peyronie's disease (pd) appears to be on the rise. this review provides an analysis of pertinent recent updates in the management of pd, focusing on data published within the past year. objective benefit from injectable agents has been reported for years in mostly noncontrolled trials. the safety and efficacy of injectable collagenase clostridium histolyticum is now supported by data from a large-scale phase iii randomized controlled trial. other important ... | 2014 | 25287257 |
| experience in the use of collagenase clostridium histolyticum in the management of peyronie's disease: current data and future prospects. | peyronie's disease (pd) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. in most cases, pd is accompanied by a physical and psychological impact. xiaflex® is an injectable collagenase clostridium histolyticum (cch) preparation consisting of a predetermined mixture of two distinct collagenases. recently the us food and drug administration (fda) approved xiaflex® for the nonsurgical tr ... | 2014 | 25276229 |
| prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for dupuytren contracture. | to compare the efficacy, tolerance, and safety of manual manipulation at day 7 to day 1 following collagenase clostridium histolyticum (cch) injection for dupuytren contracture. | 2014 | 25194768 |
| collagenase clostridium histolyticum injection for plantar fibromatosis (ledderhose disease). | 2014 | 25158740 | |
| what is the better treatment for single digit dupuytren's contracture: surgical release or collagenase clostridium histolyticum (xiapex) injection? | the purpose of this study was to compare the initial and final outcome range of motion in the mcp-j and pip-j of single digit dupuytren's contracture treated with either open surgical excision or manipulation after collagenase clostridium histolyticum (cch; xiapex) injection. | 2014 | 25155703 |
| cold intolerance following collagenase clostridium histolyticum treatment for dupuytren contracture: a molecular mechanism. | 2014 | 25154579 | |
| peyronie's disease: review and recent advances. | peyronie's disease is an incurable, sexually debilitating fibrotic disease of the penis that results in penile curvature, coital failure, and significant psychological stress for patients and their partners. appropriate treatment should be individualized and tailored to the patient's goals and expectations, disease history, physical exam findings, and erectile function. while medical treatments exist, there is little evidence to support their use. high-quality data supporting more recent advance ... | 2014 | 24984940 |
| first identification of resident and circulating fibrocytes in dupuytren's disease shown to be inhibited by serum amyloid p and xiapex. | dupuytren's disease (dd) is a common progressive fibroproliferative disorder causing permanent digital contracture. proliferative myofibroblasts are thought to be the cells responsible for dd initiation and recurrence, although their source remains unknown. dd tissue has also been shown to harbor mesenchymal and hematopoietic stem cells. fibrocytes are circulating cells that show characteristics of fibroblasts and they express surface markers for both hematopoietic and mesenchymal stromal cells. ... | 2014 | 24933153 |
| resource utilisation associated with single digit dupuytren's contracture treated with either surgery or injection of collagenase clostridium histolyticum. | the gold standard treatment for dupuytren's contracture is surgical excision of the cord. a non-surgical treatment with collagenase clostridium histolyticum injection is available but appears costly. | 2014 | 24875504 |
| acceleration of bone union after structural bone grafts with a collagen-binding basic fibroblast growth factor anchored-collagen sheet for critical-size bone defects. | bone allografts are commonly used for the repair of critical-size bone defects. however, the loss of cellular activity in processed grafts markedly reduces their healing potential compared with autografts. to overcome this obstacle, we developed a healing system for critical-size bone defects that consists of overlaying an implanted bone graft with a collagen sheet (cs) loaded with basic fibroblast growth factor (bfgf) fused to the collagen-binding domain derived from a clostridium histolyticum ... | 2014 | 24844188 |
| bioactive chitosan nanoparticles and photodynamic therapy inhibit collagen degradation in vitro. | collagen is the major structural protein of human dentin. degradation of collagen by bacterial enzymes can facilitate microbial penetration, compromise structural/interfacial integrity, and lower resistance to fracture of dentin. we evaluated the ability of photodynamic therapy (pdt), bioactive chitosan nanoparticles (csnp), or pdt in combination with csnp to inhibit bacterial collagenase-mediated degradation of collagen. | 2014 | 24767568 |
| treatment of dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system. | clinical trials seeking to establish long-term efficacy of injectable collagenase clostridium histolyticum for treatment of dupuytren disease are ongoing. in this quality improvement study, the efficacy, recurrence rate, and complications of collagenase injection for dupuytren disease are reviewed in a population of veteran patients. | 2014 | 24741384 |
| acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (xiapex) for dupuytren's contracture. | we report a case of acute (24 h) double flexor tendon rupture of the little finger after a single injection of collagenase clostridium histolyticum into a palmar dupuytren's contracture cord which caused metacarpophalangeal joint contracture. tendon surgery was performed 48 h postinjury with primary repair and standard rehabilitation but it resulted in poor active flexion due to adhesions. previous papers have suggested that a needle inserted into the flexor tendon can be detected prior to the i ... | 2014 | 24729115 |
| minimally invasive treatment of peyronie's disease: evidence-based progress. | peyronie's disease (pd) is often physically and psychologically devastating for patients, and the goal of treatment is to improve symptoms and sexual function without adding treatment-related morbidity. the potential for treatment-related morbidity after more invasive interventions, e.g. surgery, creates a need for effective minimally invasive treatments. we critically examined the available literature using levels of evidence to determine the reported support for each treatment. most available ... | 2014 | 24447536 |
| the 32nd annual j.p. morgan healthcare conference (january 13-16, 2014 - san francisco, california, usa): auxilium pharmaceuticals. | ceo and president adrian adams described auxilium pharmaceuticals as "the same as a big pharma company, only smaller." this 'specialty biopharmaceutical company' has transformed itself in the last 6 to 9 months to become the "leading men's healthcare franchise with a broad and diverse product portfolio." all of this has led to a very busy 2013, which began with the usd 600 million acquisition (q2) and integration of actient pharmaceuticals, the licensing of avanafil (stendra™) for erectile dysfu ... | 2014 | 24696871 |
| cold intolerance following collagenase clostridium histolyticum treatment for dupuytren contracture. | 2014 | 24679915 | |
| development of a förster resonance energy transfer assay for monitoring bacterial collagenase triple-helical peptidase activity. | due to their efficiency in the hydrolysis of the collagen triple helix, clostridium histolyticum collagenases are used for isolation of cells from various tissues, including isolation of the human pancreatic islets. however, the instability of clostridial collagenase i (col g) results in a degraded col g that has weak collagenolytic activity and an adverse effect on islet isolation and viability. a förster resonance energy transfer triple-helical peptide substrate (fthp) has been developed for s ... | 2014 | 24608089 |
| re: baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with peyronie's disease. | 2014 | 24602117 | |
| erosion/abrasion-preventing potential of naf and f/sn/chitosan toothpastes in dentine and impact of the organic matrix. | the study investigated the erosion/abrasion-preventing potential of experimental naf (1,400 ppm f(-)) and amine fluoride (amf)/naf/sncl2/chitosan (1,400 ppm f(-), 3,500 ppm sn(2+), 0.5% chitosan) toothpastes relative to placebo and snf2 gel (970 ppm f(-), 3,000 ppm sn(2+)), and the impact of the demineralised dentine matrix on toothpaste effects. the study was a cyclic erosion/intervention experiment (10 days). samples were stored in mineral salt solution either without or with collagenase (from ... | 2014 | 24401756 |
| pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. | the pharmacokinetics of a hybrid peptide consisting of the n-terminal biologically active region of human parathyroid hormone (pth) linked to a collagen-binding domain (cbd) were evaluated in female sprague-dawley rats. the peptide, pth-cbd, consists of the first 33 amino acids of pth linked as an extension of the amino acid chain to the cbd peptide derived from colh collagenase of clostridium histolyticum. serum concentrations arising from single dose administration by the subcutaneous and intr ... | 2014 | 24399637 |
| the efficacy and safety of collagenase clostridium histolyticum in the treatment of patients with moderate dupuytren's contracture. | the efficacy and safety of collagenase clostridium histolyticum (cch) in patients with dupuytren's contracture (dc) was demonstrated in a program including two pivotal phase 3 clinical trials (cord i and ii) which included patients with a broad range of disease severity. this analysis assessed the efficacy and safety of cch in the subpopulation of dc patients with up to two joints affected and moderate disease according to british society of surgery of the hand classification. this was in suppor ... | 2014 | 24397625 |
| efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple dupuytren contractures. | to assess the safety and efficacy of 2 concurrent injections of collagenase clostridium histolyticum (cch) in the same hand to treat multiple dupuytren flexion contractures. | 2014 | 24315486 |
| re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. | 2014 | 24289857 | |
| efficacy and safety of collagenase clostridium histolyticum injection for dupuytren contracture: report of 40 cases. | dupuytren's disease (dd) is a fibroproliferative pathology that affects the palmar aponeurosis causing the development of nodules and collagen cords and the progressive flexion of the fingers. the standard procedure is surgical fasciectomy, followed by high recurrence rates. collagenase clostridium histolyticum (cch) injection represents an innovative noninvasive approach to the treatment of dd. this prospective study was designed to examine the efficacy and safety of cch injection performed in ... | 2014 | 24254968 |
| re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies: m. gelbard, i. goldstein, w. j. hellstrom, c. g. mcmahon, t. smith, j. tursi, n. jones, g. j. kaufman and c. c. carson, iii j urol 2013; 190: 199-207. | 2014 | 24239419 | |
| acceleration of bone formation during fracture healing by injectable collagen powder and human basic fibroblast growth factor containing a collagen-binding domain from clostridium histolyticum collagenase. | growth factor delivered with implantable biomaterials has been used to both accelerate and ensure healing of open fractures in human patients. however, a major limitation of implantable biomaterials is the requirement for open surgical placement. here, we developed an injectable collagen material-based bone formation system consisting of injectable collagen powder with fibril morphology and collagen triple helix conformation, and basic fibroblast growth factor (bfgf) fused to the collagen-bindin ... | 2014 | 24124060 |
| analysis of efficacy and safety of treatment with collagenase clostridium histolyticum among subgroups of patients with dupuytren contracture. | collagenase clostridium histolyticum (cch) injection is a nonoperative treatment of hand contractures from dupuytren disease. this study assessed the efficacy and safety of cch in several subgroups of patients with increased surgical risk.data were pooled from 3 randomized, placebo-controlled, double-blind trials. this analysis included 271 patients with metacarpophalangeal (n = 167) or proximal interphalangeal (n = 104) joint contractures greater than or equal to 20 degrees treated with cch (0. ... | 2014 | 23511746 |
| [treatment of dupuytren's disease with collagenase - a 1-year follow-up of 37 patients]. | the efficiency of collagenase of clostridium histolyticum (cch; xiapex) in the treatment of dupuytren's contracture has been proved in phase iii studies. this retrospective study aims to evaluate our clinical results after the use of cch. | 2014 | 25564949 |
| postapproval clinical experience in the treatment of dupuytren's contracture with collagenase clostridium histolyticum (cch): the first 1,000 days. | dupuytren's contracture is a benign fibromatosis of the palmar and digital fascia of the hand of uncertain etiology, resulting in nodules and cords beneath the skin of the palm of the hands that may lead to the development of contractures. surgical intervention is often considered when metacarpophalangeal (mp) joint contracture is 30° or more, or when there is any degree of proximal interphalangeal (pip) joint contracture. collagenase clostridium histolyticum (cch) is a nonsurgical, minimally in ... | 2014 | 25414604 |
| acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from clostridium histolyticum collagenase. | basic fibroblast growth factor 2 (bfgf) is a potent mitogen for mesenchymal cells, and the local application of recombinant bfgf accelerates bone union and defect repair. however, repeated dosing is required for sustained therapeutic effect as the efficacy of bfgf decreases rapidly following its diffusion from bone defect sites. here, we attempted to develop a collagen-based bone formation system using a fusion protein (collagen binding-bfgf, cb-bfgf) consisting of bfgf and the collagen-binding ... | 2014 | 23775724 |
| surgical findings in the treatment of dupuytren's disease after initial treatment with clostridial collagenase (xiaflex). | we investigated the difficulty of surgical fasciectomy after previous treatment with clostridial collagenase injection. the 35 clinicians who had participated in the initial trials of this injection were contacted via email. twenty-eight responded, nine of whom reported on 15 patients. most (seven of nine) felt there was no significant distortion of anatomy and rated the level of technical difficulty as equivalent to a primary dupuytren's fasciectomy at the observed degree of contracture (nine o ... | 2014 | 23649016 |
| proteomic protease specificity profiling of clostridial collagenases reveals their intrinsic nature as dedicated degraders of collagen. | clostridial collagenases are among the most efficient degraders of collagen. most clostridia are saprophytes and secrete proteases to utilize proteins in their environment as carbon sources; during anaerobic infections, collagenases play a crucial role in host colonization. several medical and biotechnological applications have emerged utilizing their high collagenolytic efficiency. however, the contribution of the functionally most important peptidase domain to substrate specificity remains unr ... | 2014 | 24125730 |
| purification and fermentation in vitro of sesaminol triglucoside from sesame cake by human intestinal microbiota. | sesaminol triglucoside (stg), the most abundant lignan glycoside existing in sesame cake/meal, has exhibited various biological activities. however, little information about its in vitro fermentation with intestinal microbiota is available. therefore, the effect of stg from sesame cake on the fermentation of human fecal microbiota was evaluated. first, high-purity stg was successfully prepared from defatted sesame cake by extraction with 80% ethanol and simple purification procedures of polyamid ... | 2013 | 23387872 |
| cytokine response of human mononuclear cells induced by intestinal clostridium species. | altered composition of intestinal microbiota has been associated with various immunological disorders such as inflammatory bowel disease. although clostridium species are major inhabitants of the intestinal tract, their interaction with the host immunological system is yet poorly characterized. in this study, cytokine responses of human monocytic cell line thp-1 and peripheral blood mononuclear cells (pbmc) to six type strains representing common intestinal clostridial species were determined. t ... | 2013 | 23168133 |
| solution structure of clostridial collagenase h and its calcium-dependent global conformation change. | collagenase h (colh) from clostridium histolyticum is a multimodular protein composed of a collagenase module (activator and peptidase domains), two polycystic kidney disease-like domains, and a collagen-binding domain. the interdomain conformation and its changes are very important for understanding the functions of colh. in this study, small angle x-ray scattering and limited proteolysis were employed to reveal the interdomain arrangement of colh in solution. the ab initio beads model indicate ... | 2013 | 23561530 |
| highly sensitive single-fibril erosion assay demonstrates mechanochemical switch in native collagen fibrils. | it has been established that the enzyme susceptibility of collagen, the predominant load-bearing protein in vertebrates, is altered by applied tension. however, whether tensile force increases or decreases the susceptibility to enzyme is a matter of contention. it is critical to establish a definitive understanding of the direction and magnitude of the force versus catalysis rate (k c ) relationship if we are to properly interpret connective tissue development, growth, remodeling, repair, and de ... | 2013 | 22584606 |
| collagenase inhibitors from viola yedoensis. | fractionation of acetone and methanol extracts of viola yedoensis, under the guidance of inhibition against clostridium histolyticum collagenase (chc), resulted in the isolation of esculetin (1) (ic(50) 12 μm) and scopoletin (2) (ic(50) 1.8 μm) as the active constituents, together with trans-p-coumaric acid (3), cis-p-coumaric acid (4), 3-o-β-d-glucosyl-7-o-α-l-rhamnosylkaempferol (5), rutin (6), isovitexin (7), isoorientin (8), vicenin-2 (9), isoscoparin (10), vanillic acid (11) and adenosine ( ... | 2013 | 22529049 |
| budget impact analysis in spanish patients with dupuytren's contracture: fasciectomy vs. collagenase clostridium histolyticum. | the aim of this study was to estimate the budget impact of collagenase clostridium histolyticum (cch) vs. fasciectomy (fsc) surgery for the treatment of dupuytren's disease (dd) in spain. a cost minimization analysis was adopted (effectiveness was assumed to be equivalent for both techniques). dd related costs were considered. cch costs (including drug, administration and visits) were obtained from clinical trials and a real-life study. fsc costs (including type of admission, visits, operating r ... | 2013 | 23507313 |
| correction of infraorbital dark circles using collagenase-digested fat cell grafts. | a number of factors, including visibility of the orbicularis oculi muscle through thin skin, can cause dark circles around the eyes. fat grafts have been used to augment the lower eyelid skin to correct dark circles, but irregularities caused by leaving visible lumps of the fat can occur. we used collagenase-digested fat cell grafts to correct these deformities. | 2013 | 23437990 |
| skin graft loss resulting from collagenase clostridium histolyticum treatment of dupuytren contracture: case report and review of the literature. | treatment of dupuytren disease with collagenase clostridium histolyticum is increasingly used among hand surgeons. although it is generally safe and efficacious, complications related to enzymatic fasciotomy occur. postapproval surveillance and communication among hand surgeons continues to refine the indications, contraindications, and complications recognized in the treatment of dupuytren disease with enzymatic therapy. major treatment-related adverse events previously reported include flexor ... | 2013 | 23391354 |
| bother and distress associated with peyronie's disease: validation of the peyronie's disease questionnaire. | we validated the peyronie's disease questionnaire (http://www.auxilium.com/pdq), a 15-question self-reported survey that measures the impact and severity of peyronie's disease symptoms in 3 domains, including 1) psychological and physical symptoms, 2) penile pain and 3) symptom bother. | 2013 | 23376705 |
| clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. | impress (investigation for maximal peyronie's reduction efficacy and safety studies) i and ii examined the clinical efficacy and safety of collagenase clostridium histolyticum intralesional injections in subjects with peyronie disease. co-primary outcomes in these identical phase 3 randomized, double-blind, placebo controlled studies included the percent change in the penile curvature abnormality and the change in the peyronie disease questionnaire symptom bother score from baseline to 52 weeks. | 2013 | 23376148 |
| efficacy and safety of collagenase clostridium histolyticum injection for dupuytren contracture: short-term results from 2 open-label studies. | the joint i (united states) and joint ii (australia and europe) studies evaluated the efficacy and safety of collagenase clostridium histolyticum (cch) injection for the treatment of dupuytren contracture. | 2013 | 23218556 |
| dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (cordless study): 3-year data. | to evaluate long-term efficacy and safety of collagenase clostridium histolyticum (cch) after the third year of a 5-year nontreatment follow-up study, collagenase option for reduction of dupuytren long-term evaluation of safety study. | 2013 | 23200951 |
| structural comparison of colh and colg collagen-binding domains from clostridium histolyticum. | clostridium histolyticum secretes collagenases, colg and colh, that cause extensive tissue destruction in myonecrosis. the c-terminal collagen-binding domain (cbd) of collagenase is required for insoluble collagen fibril binding and subsequent collagenolysis. the high-resolution crystal structures of colg-cbd (s3b) and colh-cbd (s3) are reported in this paper. the new x-ray structure of s3 was solved at 2.0-å resolution (r = 17.4%; r(free) = 23.3%), while the resolution of the previously determi ... | 2013 | 23144249 |
| in vitro fermentation of grape seed flavan-3-ol fractions by human faecal microbiota: changes in microbial groups and phenolic metabolites. | with the aim of investigating the potential of flavan-3-ols to influence the growth of intestinal bacterial groups, we have carried out the in vitro fermentation, with human faecal microbiota, of two purified fractions from grape seed extract (gse): gse-m (70% monomers and 28% procyanidins) and gse-o (21% monomers and 78% procyanidins). samples were collected at 0, 5, 10, 24, 30 and 48 h of fermentation for bacterial enumeration by fluorescent in situ hybridization and for analysis of phenolic m ... | 2013 | 23121387 |
| baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with peyronie's disease. | peyronie's disease (pd) is a localized penile collagen disorder of the tunica albuginea associated with significant physical deformity and psychological impairment. current understanding of pretreatment characteristics in patients with chronic pd is limited by small samples, varied quality of assessments, and the lack of a pd-specific, validated measure of the psychosexual impact of pd. | 2013 | 24112401 |
| isolated and spontaneous correction of proximal interphalangeal joint contractures in dupuytren's disease: an exploratory analysis of the efficacy and safety of collagenase clostridium histolyticum. | dupuytren's contractures affecting proximal interphalangeal (pip) joints are challenging to treat. we explored the effects of collagenase clostridium histolyticum (cch) on pip joint contractures after injection of an affected metacarpophalangeal (mp) joint in the same finger and after injection of an isolated pip joint contracture. | 2013 | 24092562 |
| [treatment of dupuytren's disease using collagenase from clostridium histolyticum]. | the collagenase from clostridium histolyticum is a new therapeutic option, and the first pharmacological one, in the treatment of dupuytren's disease. | 2013 | 24071041 |
| effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. | to evaluate the impact of early prebiotic and probiotic intervention on preterm infants' well-being, crying, growth, and microbiological programming. | 2013 | 23915796 |
| understanding the course of peyronie's disease. | to correct common misconceptions about peyronie's disease (pd) that present obstacles to early recognition and treatment. | 2013 | 23869679 |
| [treatment of dupuytren's contracture by collagenase injection]. | dupuytren's disease is a disorder of the palmar aponeurosis responsible for apparition of pathological collagen cords that will gradually lead to a digital retraction. these cords cause functional disability to the hand with a real handicap for the patient. no curative treatment exists currently in this disease. injections of collagenase from clostridium histolyticum cause lysis of the collagen present in the cords and cause an interruption of the palmar cord. it is a new treatment in the manage ... | 2013 | 23856551 |
| oceanirhabdus sediminicola gen. nov., sp. nov., an anaerobic bacterium isolated from sea sediment. | a novel anaerobic bacterium, designated nh-jn4(t) was isolated from a sediment sample collected in the south china sea. cells were gram-stain-positive, spore-forming, peritrichous and rod-shaped (0.5-1.2×2.2-7 µm). the temperature and ph ranges for growth were 22-42 °c and ph 6.0-8.5. optimal growth occurred at 34-38 °c and ph 6.5-7.0. the nacl concentration range for growth was 0.5-6 % (w/v) with an optimum of 2.5 %. catalase and oxidase were not produced. substrates which could be utilized wer ... | 2013 | 23811141 |
| [news in the treatment of dupuytren's disease: from surgery to collagenase's injection]. | dupuytren's disease is a benign fibromatosis affecting the palmar and digital fascia and causing flexion contracture of the affected fingers. up to date, this affection has no curative treatment available. the author is presenting an updated review of the therapeutic arsenal available for dupuytren's disease cords correction. open fasciectomy remains the "gold standard" surgical treatment of the disease but enzymatic treatment of the cords by injected collagenase clostridium histolyticum represe ... | 2013 | 24195241 |
| collagenase clostridium histolyticum for dupuytren contracture: patterns of use and effectiveness in clinical practice. | to collect data on the real-world effectiveness of collagenase clostridium histolyticum (cch) during its first year of use following u.s. food and drug administration approval and compare those results with clinical trial efficacy data. | 2013 | 24140362 |
| use of resources and costs associated with the treatment of dupuytren's contracture at an orthopedics and traumatology surgery department in denia (spain): collagenase clostridium hystolyticum versus subtotal fasciectomy. | our purpose was to analyze and compare the use of direct health resources and costs generated in the treatment of dupuytren's contracture using two different techniques: subtotal fasciectomy and infiltration with collagenase clostridium histolyticum (cch) in regular clinical practice at the orthopedic and traumatology surgery (ots) department at the hospital de denia (spain). | 2013 | 24125161 |
| functional outcome of collagenase injections compared with fasciectomy in treatment of dupuytren's contracture. | this study was designed to provide comparative information on the safety and efficacy of injection with collagenase clostridium histolyticum (cch) and fasciectomy for patients with dupuytren's contracture (dc). | 2013 | 24426958 |
| examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for dupuytren's disease. | this study examined the efficacy, complications, and contracture recurrence in patients who received injectable collagenase clostridium histolyticum (cch) for dupuytren's-induced metacarpophalangeal (mp) and proximal interphalangeal (pip) joint contractures. | 2013 | 24426932 |
| impact of protease inhibitors on dentin matrix degradation by collagenase. | this proof-of-concept study assessed whether the reduction of the degradation of the demineralized organic matrix (dom) by pre-treatment with protease inhibitors (pi) is effective against dentin matrix loss. bovine dentin slices were demineralized with 0.87 m citric acid, ph 2.3, for 36 hrs. in sequence, specimens were treated or not (ut, untreated) for 1 min with gels containing epigallocatechin 3-gallate (egcg, 400 µm), chlorhexidine (chx, 0.012%), feso(4) (1 mm), naf (1.23%), or no active com ... | 2012 | 23023765 |
| late complications of clinical clostridium histolyticum collagenase use in dupuytren's disease. | while dupuytren's disease can cause disabling contractures requiring open surgery, a less-invasive option using clostridium histolyticum collagenase (chc) via percutaneous injection was recently reported. a recent prospective, randomized trial demonstrated few complications during 90 days follow-up, however did not assess any longer term follow-up for these patients. long-term outcomes in this setting have not been adequately reported, and the current manuscript aims to identify late complicatio ... | 2012 | 22912868 |
| bacterial collagen-binding domain targets undertwisted regions of collagen. | clostridium histolyticum collagenase causes extensive degradation of collagen in connective tissue that results in gas gangrene. the c-terminal collagen-binding domain (cbd) of these enzymes is the minimal segment required to bind to a collagen fibril. cbd binds unidirectionally to the undertwisted c-terminus of triple helical collagen. here, we examine whether cbd could also target undertwisted regions even in the middle of the triple helix. collageneous peptides with an additional undertwisted ... | 2012 | 22898990 |
| clostridium histolyticum collagenase in the treatment of dupuytren's contracture. | dupuytren's disease is a common, costly and recurrent health issue. this review compares clostridium histolyticum collagenase with current operative treatments. collagenase management is an effective non-surgical alternative associated with lower risks of serious adverse events, but higher incidence of non-serious adverse events. | 2012 | 22875519 |
| development and validation of novel enzyme activity methods to assess inhibition of matrix metalloproteinases (mmps) in human serum by antibodies against enzyme therapeutics. | this paper summarizes the development and validation of five enzyme activity methods to assess the specific inhibition of human endogenous matrix metalloproteinases mmp-1 (interstitial collagenase), mmp-2 (gelatinase a), mmp-3 (stromelysin 1), mmp-8 (collagenase 2) and mmp-13 (collagenase 3) by anti-collagenase clostridium histolyticum (cch) antibodies in human serum. these mmps are of interest since antibodies against a therapeutic enzyme may cross-react with, and inactivate, the mmps. the vali ... | 2012 | 22854133 |
| conformational dynamics accompanying the proteolytic degradation of trimeric collagen i by collagenases. | collagenases are the principal enzymes responsible for the degradation of collagens during embryonic development, wound healing, and cancer metastasis. however, the mechanism by which these enzymes disrupt the highly chemically and structurally stable collagen triple helix remains incompletely understood. we used a single-molecule magnetic tweezers assay to characterize the cleavage of heterotrimeric collagen i by both the human collagenase matrix metalloproteinase-1 (mmp-1) and collagenase from ... | 2012 | 22720833 |
| efficacy of collagenase in patients who did and did not have previous hand surgery for dupuytren's contracture. | collagenase clostridium histolyticum (cch) is a non-surgical, efficacious therapy for dupuytren's contracture (dc). this study evaluated the efficacy and safety of cch in patients with previous dc surgery. data from 12 cch clinical trials were pooled. at screening, patients provided details about the type/date of previous dc surgery. reviewers coded descriptions to the operated hand, finger, and joint. of 1082 patients, 422 (39%) had previous dc surgery. for these patients with previous surgery, ... | 2012 | 22670890 |
| investigation of the impact of feeding lactobacillus plantarum crl 1815 encapsulated in microbially derived polymers on the rat faecal microbiota. | the aim of this study was to evaluate the impact of the administration of microencapsulated lactobacillus plantarum crl 1815 with two combinations of microbially derived polysaccharides, xanthan : gellan gum (1%:0·75%) and jamilan : gellan gum (1%:1%), on the rat faecal microbiota. | 2012 | 22612542 |
| retraction: late complications of clinical clostridium histolyticum collagenase use in dupuytren's disease. | 2012 | 23144771 | |
| phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with peyronie disease. | collagenase clostridium histolyticum is an investigational nonsurgical treatment for peyronie disease. in this phase 2b, double-blind, randomized, placebo controlled study we determined the safety and efficacy of collagenase c. histolyticum and assessed a patient reported outcome questionnaire. | 2012 | 22503048 |
| recent surgical and medical advances in the treatment of dupuytren's disease - a systematic review of the literature. | dupuytren's disease (dd) is a type of fibromatosis which progressively results in the shortening and thickening of the fibrous tissue of the palmar fascia. this condition which predominantly affects white-northern europeans has been identified since 1614. dd can affect certain activities of daily living such as face washing, combing hair and putting hand in a glove. the origin of dupuytren's contracture is still unknown, but there are a number of treatments that doctors have come across througho ... | 2012 | 22431952 |
| in vitro study of novel collagenase (xiaflex®) on dupuytren's disease fibroblasts displays unique drug related properties. | dupuytren's disease (dd) is a benign, fibroproliferative disease of the palmar fascia, with excessive extracellular matrix (ecm) deposition and over-production of cytokines and growth factors, resulting in digital fixed flexion contractures limiting hand function and patient quality of life. surgical fasciectomy is the gold standard treatment but is invasive and has associated morbidity without limiting disease recurrence. injectable collagenase clostridium histolyticum (cch)--xiaflex®--is a nov ... | 2012 | 22384021 |
| assessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase clostridium histolyticum antibodies in human sera obtained from patients with dupuytren's contracture. | collagenase clostridium histolyticum (cch) contains a fixed ratio of class i (aux-i) and class ii (aux-ii) collagenases and is used as treatment for dupuytren's contracture. these two zn-dependent enzymes, produced by the gram-positive bacterium clostridium histolyticum, are related functionally to matrix metalloproteinases (mmps) which, among other functions, degrade the extracellular matrix. since aux-i and aux-ii exhibit sequence similarities to human mmps, we assessed mmp-1 (interstitial col ... | 2012 | 22357647 |
| a new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. | the optimal enzyme blend that maximizes human islet yield for transplantation remains to be determined. in this study, we evaluated eight different enzyme combinations (ecs) in an attempt to improve islet yield. the ecs consisted of purified, intact or truncated class 1 (c1) and class 2 (c2) collagenases from clostridium histolyticum (ch), and neutral protease (np) from bacillus thermoproteolyticus rokko (thermolysin) or ch (chnp). | 2012 | 22318245 |
| in vitro fermentation of a red wine extract by human gut microbiota: changes in microbial groups and formation of phenolic metabolites. | an in vitro batch culture fermentation experiment was conducted with fecal inocula from three healthy volunteers in the presence and absence of a red wine extract. changes in main bacterial groups were determined by fish during a 48 h fermentation period. the catabolism of main flavonoids (i.e., flavan-3-ols and anthocyanins) and the formation of a wide a range of phenolic microbial metabolites were determined by a targeted uplc-pad-esi-tq ms method. statistical analysis revealed that catechol/p ... | 2012 | 22313337 |